The "Global Pelvic Floor Electric Stimulator Market" is predicted to reach at a high CAGR of 11.5% during the forecast period (2022-2029).
Electrical stimulation of the pelvic floor is a painless and effective procedure that treats urinary incontinence, frequency and urgency.
PFS involves electrical stimulation of pelvic floor muscles using either a probe wired to a device for controlling the electrical stimulation or, more recently, extracorporeal electromagnetic (also called magnetic) pulses.
Source: DataM Intelligence Analysis (2021)
The major factors driving the growth of this market are the growing prevalence of neurodegenerative disorders, the growing geriatric population and the increasing use of medical devices in various treatments.
The growing geriatric population will drive the market growth
The prevalence of urinary incontinence (UI) and overactive bladder rises with age, and older adults are the fastest-growing population segment.
According to WHO prevalence of urinary incontinence reported in population-based studies ranges from 9.9% to 36.1% (2–4) and is twice as high in older women as in older men.
As per the American Society of Nephrology, urologic diseases are the third most common concern among the geriatric population, and these account for approximately around 47.0% of physician visits. Similarly, according to Phoenix Physical Therapy, 200 million people are affected by urinary incontinence worldwide. Moreover, the rising elderly population in the Asia Pacific region, especially in Japan, India, and China, is expected to drive the market during the forecast period.
R&D and the increasing use of medical devices for various treatments are driving the market growth
The increase in technological innovations in the healthcare system may increase the demand for medical devices for various treatments. This will increase Pelvic Floor Electric Stimulator Market in the forecast period. Increasing investments in research and development towards solutions for weak pelvic floor muscle.
The high cost of pelvic floor electric stimulator may hamper the growth
Due to the high cost of pelvic floor electric stimulators, the growth in the market may get affected, as people may lookout for cheaper and alternative treatments. Some patients may not pay the expense for the treatment, which their health insurance may not cover.
COVID-19 Impact Analysis
The COVID-19 has impacted most healthcare systems globally and has a notable impact on the market. With all social distancing norms, all offline consultation sessions have been held for a while. Pelvic exercises are increasingly recommended to patients suffering from urinary incontinence during the COVID-19 pandemic. The demand for pelvic floor electrical stimulation devices is expected to remain steady. Thus, the COVID-19 pandemic has affected the market. However, the situation is expected to improve gradually in the forecast period.
Mobile pelvic floor electrical stimulation devices is expected to grow at the fastest CAGR during the forecast period (2021-2028)
Mobile pelvic floor electrical stimulation has rapidly become the preferred option for healthcare professionals and patients. Low cost of mobile devices compared with fixed devices, high level of portability with easy access to patients in-home care settings. With the growing senior population, the mobile pelvic floor electrical stimulation devices market will increase the market in the forecast period.
Urinary incontinence treatment is expected to grow in the forecast period.
Pelvic floor electrical stimulation devices are primarily used for incontinence issues. Of the total women having incontinence, the highest numbers were found to have stress incontinence [73.8% followed by mixed [16.8% and urge incontinence [9.5%]. Out of 3000 women, 656 women reported urinary incontinence, and prevalence was 21.87%. Urinary infection is seen in 11-34% of older men, with 2-11% reporting daily UI.
Hospitals are projected to account for the significant market share
Owing to a large number of patients and developing healthcare facilities at hospitals. Also, hospitals provide better assistance and leverage higher investment capabilities and capital, with better access to cutting-edge technologies.
North America holds the largest share in the market
This dominance can be attributed to the increasing incidence of neurodegenerative diseases, rising geriatric population and increasing prevalence of sexual dysfunction.
Population-based data on 36 million Medicare beneficiaries over 65 suggests that 1.6% of Americans are treated yearly for Parkinson's disease. According to the age- and sex-specific meta-estimates from California, Minnesota, and Ontario and the US population structure from 2010, we estimate the overall prevalence of Parkinson's disease among those aged ≥45 years to be 572 per 100,000 (95% confidence interval 537–614) that there were 680,000 individuals in the US aged ≥45 years with PD in 2010 and that that number will rise to approximately 930,000 in 2020 and 1,238,000 in 2030 based on the US Census Bureau population projections.
According to Parkinson's Foundation, nearly one million people in the U.S. live with Parkinson's disease (PD), which is more than the combined number of people diagnosed with multiple sclerosis, muscular dystrophy and Lou Gehrig's disease (or Amyotrophic Lateral Sclerosis). This is expected to rise to 1.2 million by 2030.
Source: DataM Intelligence Analysis (2020)
The primary key players dominating the pelvic floor electrical stimulation market are Everyway Medical Instruments Co., Ltd, InControl Medical, Laborie, Inc., The Prometheus Group, Utah Medical Products, Inc., Tic Medizintechnik GmbH & CO. KG, Cleo, Shenzhen XFT Medical Limited, Sugar International, Sunmedix Co, Ltd., Verity Medical Ltd, Novuqare, Relevium Labs Inc., GymnaUniphy, V2U Healthcare, Shenzhen Konmed Technology Co.ltd, Guangzhou Bytech Technology Co., Ltd, Shanghai Tiran Industrial Co., Ltd and Atlantic Therapeutics.
Pelvic Floor Electric Stimulator Market Key Companies to Watch
Overview: Atlantic Therapeutics develops professional and consumer medical devices, related software, apps and connected health technologies to treat all types of incontinence, sexual health dysfunctions, and other associated disorders by strengthening muscles and modulating nerves of the pelvic floor. All Atlantic Therapeutics products are approved under the European Medical Devices Directive 93/42/EEC. Atlantic Therapeutics focuses on treating incontinence, sexual health dysfunctions and other associated disorders. It is on a mission to help millions of people suffering globally by strengthening the muscles and modulating the nerves of the pelvic floor.
Product Portfolio: The company offers to develop and manufacture medical device-quality pelvic floor strengthening and nerve stimulation products, backed by strong clinical evidence and subjected to controlled trials.
Key Development: Atlantic Therapeutics Group Ltd has recently successfully completed a € YY million growth capital financing, enabling the company to move forward with next phase of growth and treat millions of people across the globe who suffer from bladder weakness, clinically known as stress urinary incontinence.
The Pelvic Floor Electric Stimulator Market report would provide access to an approx. 61 market data table, 53 figures and 180 pages.
Get your free sample proposal with a single click!